Microbiome Market Definition

The microbiome market consists of sales of microbiome and related services used as immunotherapeutic agents in the pharmaceutical industry. Microbiomes are used as immunotherapy for a wide variety of conditions, including infectious diseases, endocrine and metabolic disorders, inflammatory conditions, cancers, irritable bowel syndrome, neurological disorders, hematological disorders and cardiovascular diseases. The microbiome consists of the genetic material within a microbiota, which is the collection of microorganisms, such as bacteria, archaea, fungi, and viruses living in humans, animals, plants, soil and other habitats. For example, the gut microbiome consists of collective genome of microbes inhabiting the gut. Microbiomes are also known as the metagenome of the microbiota.

Drug discovery is the process of identifying biologically active compounds that possess the potential to become therapeutic agents. The drug discovery process involves different phases, from ideation to development to approval. It is used to discover a new clinical drug for treating new, existing, and previously incurable diseases. The main types of drugs in the drug discovery market are small molecule and large molecule. The small molecules are used to identify small molecules with suitable properties for development. Small molecule refers to a low molecular weight drug that can smoothly penetrate cells. The various processes in drug discovery includes target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. The various technologies in drug discovery includes high throughput screening, spectroscopy, combinatorial chemistry, biochips, pharmacogenomics and pharmacogenetics, bioinformatics, metabolomics, nanotechnology, and other technologies. The drug discovery is applied in many therapeutic areas such as oncology, neurology, infectious and immune system diseases, digestive system diseases, cardiovascular diseases, diabetes, respiratory disease, and other therapeutic areas. The drug discovery is used by pharmaceutical companies, CROs, and other end-users. The drug discovery market research report is one of a series of new reports from The Business Research Company that provides drug discovery market statistics, including drug discovery industry global market size, regional shares, competitors with a drug discovery market share, detailed drug discovery market segments, market trends and opportunities, and any further data you may need to thrive in the drug discovery industry. This drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global drug discovery market size grew from $85.42 billion in 2022 to $98.48 billion in 2023 at a compound annual growth rate (CAGR) of 15.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The drug discovery market size is expected to grow to $158.67 billion in 2027 at a CAGR of 12.7%. Rising healthcare expenditure is expected to propel the drug discovery market going forward. Countries around the world are spending a major share of their GDP on healthcare expenses which include hospital care, physician and clinical services, other professional services, dental services, other health, residential, and personal care, home health care, nursing care facilities, and continuing care retirement communities, prescription drugs, and others. Drug discovery holds a significant part of the health expenditure, as it is required to treat diseases and prolong life. There is an increasing need for new drugs to treat new diseases. For instance, In 2020, the US National Healthcare Expenditure (NHE) grew by 9.7% to $4.1 trillion, accounting for 19.7% of the U.S. Gross Domestic Product (GDP). Therefore, rising healthcare expenditure is expected to propel the drug discovery market. Technological advancements are a key trend in the drug discovery market. Companies operating in the drug discovery market are coming up with various new technologies, such as AI, imaging technology, and others, to reduce the time required for drug discovery. The imaging technology enables non-invasive biological activities occurring within organisms in response to medications to be visualised, characterised, and quantified. These methods, which make use of the strengths of either probes or tissue itself, are crucial for understanding diseases and finding new treatments. For instance, in October 2020, the CU Skaggs School of Pharmacy and Pharmaceutical Sciences, part of Colorado Anschutz, a US-based medical university, announced a new drug discovery technology that includes a new robotic screening and imaging technology which cuts the screening time for new drug therapies by half and also enables rapid and cost-effective screening of hundreds of thousands of potential therapies for diseases. In October 2021, Inotiv, a US-based contract research organization that focuses on nonclinical and analytical drug discovery and development services, acquired Plato BioPharma for $15 million. Through this acquisition, Inotiv intends to execute its strategy of developing a comprehensive range of contract research services spanning the entire drug discovery and preclinical development process. Plato BioPharma is a US-based company specialising in vivo pharmacology research and drug discovery in the cardiovascular, renal, pulmonary, and hepatic therapeutic areas. Major players in the drug discovery market are Pfizer Inc., GlaxoSmithKline PLC, Merck & Co. Inc., Agilent Technologies Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Bayer AG, Abbott Laboratories Inc., AstraZeneca PLC, Shimadzu Corp., Evotec SE, Boehringer Ingelheim, Inc., Novartis, Johnson & Johnson, and WIL Research Laboratories. North America was the largest region in the drug discovery market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The drug discovery market includes revenues earned by entities by high throughput screening, spectroscopy, combinatorial chemistry, biochips, pharmacogenomics and pharmacogenetics, bioinformatics, metabolomics, and nanotechnology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global drug discovery market is segmented - 1) By Drug Type: Small Molecule, Large Molecule 2) By Process: Target Selection, Target Validation, Hit-to-Lead Identification, Lead Optimization, Candidate Validation 3) By Technology: High Throughput Screening, Spectroscopy, Combinatorial Chemistry, Biochips, Pharmacogenomics and Pharmacogenetics, Bioinformatics, Metabolomics, Nanotechnology, Other Technologies 4) By Therapeutic Area: Oncology, Neurology, Infectious and Immune System Diseases, Digestive System Diseases, Cardiovascular Diseases, Diabetes, Respiratory Disease, Other Therapeutic Areas 5) By End User: Pharmaceutical Companies, CROs, Other End-Users

Hematology diagnostic devices and equipment are used to diagnose diseases related to blood, vascular systems, bone marrow, autoimmune disorders, and hemostasis. The main products of the hematology diagnostics devices and equipment are instruments and consumables. Hematology diagnostic instruments are used to diagnose diseases related to blood, vascular systems, bone marrow, autoimmune disorders, and hemostasis. The hematology diagnostics consumables involved are reagents, stains, and others, and the hematology diagnostics instruments involved are analyzers, flow cytometers, and others. These are used in various applications, including drug testing, autoimmune disease, cancer, diabetes mellitus, infectious disease, and others. The end-users are hospitals, specialized diagnostic centres, and specialized research institutes. The hematology diagnostics devices and equipment market research report is one of a series of new reports from The Business Research Company that provides hematology diagnostics devices and equipment market statistics, including hematology diagnostics devices and equipment industry global market size, regional shares, competitors with a hematology diagnostics devices and equipment market share, detailed hematology diagnostics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the hematology diagnostics devices and equipment industry. This hematology diagnostics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hematology diagnostic devices and equipment market size will grow from $1.89 billion in 2022 to $2.12 billion in 2023 at a compound annual growth rate (CAGR) of 12.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hematology diagnostic devices and equipment market size is expected to grow to $3.04 billion in 2027 at a CAGR of 9.4%. Hematology diagnostic devices are driven by the increase in the prevalence of blood disorders. Hematology diagnostic devices are widely used to identify the type of blood disorder. A blood disorder is a condition which is impacting the count of the blood cells like red blood cells, white blood cells, platelets, etc. Blood disorders affect millions of people each year across the world irrespective of age, race, and sex. E.g. As per the World Health Organization, Hemoglobin disorder is affecting 75% of the total births globally and the prevalence of Anemia is 12.7% in men. Product recall is one of the major problems that companies are facing. Product recalls are the process of returning faulty devices which can be due to errors in the manufacturing of the device. Because of the faulty devices tests conducted in the diagnostic centres may get affected. For example, Becton Dickinson (BD) and Company recalled Vacutainer EDTA Blood Collection Tubes because they are affecting the test due to the chemical interference of test tubes with the blood samples. This recall was classified as Class I recall, the most serious type of recall, by the Food and Drug Administration (FDA). Such product recalls can negatively affect market growth. Companies in the field of hematology diagnostic devices are increasingly investing in automation technology. Automation technology advancements are driving the demand for hematology analyzers, and this automation will reduce the errors caused by the manual practices in the diagnostic centres. For example, top companies like Sysmex acquired a CLIA waiver for a new automated hematology analyzer, and by selling this product, Sysmex makes it possible for clinical facilities to perform hematology testing without any manual errors. CLIA regulations establish quality standards for laboratory testing performed on specimens from humans, such as blood, body fluid, and tissue, for diagnosis, prevention, or treatment of disease, or assessment of health. The hematology diagnostic devices market has a potential market to grow rapidly but stringent regulatory policies are restricting their growth. The FDA currently regulates class I, class II, and class III hematology devices. This means that class I hemostasis devices are regulated to use these devices are exempt from the premarket notification requirements and they only be used for the general controls. Regulations for class II devices are exempt from the premarket notification requirements and they can be used for special controls. Class III is the most stringent category as it requires premarket approval (PMA). Major players in the hematology diagnostics devices and equipment market are Abbott Diagnostics, Beckman Coulter, Bio-Rad Laboratories, Drucker Diagnostics, Horiba Ltd., Instrumentation Laboratory Inc., Siemens Healthcare, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., F. Hoffmann-La Roche AG, and Thermo Fisher Scientific Inc. North America was the largest region in the global hematology diagnostics devices and equipment market in 2022. Asia-Pacific was the second-largest region in the hematology diagnostics devices and equipment market. The regions covered in global hematology diagnostics devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the hematology diagnostic devices are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The hematology diagnostic devices and equipment market consists of sales of flow cytometers, slide strainers, automated cell counters, red cell indices devices, micro sedimentation centrifuges, or blood volume measuring devices, occult blood tests, platelet aggregometer, erythrocyte sedimentation rate tests, red blood cell enzyme assay kits, glutathione reductase assays, and hematology reagents that are used for the diagnosis of hematology. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global hematology diagnostic devices and equipment market is segmented - 1) By Product: Instruments, Consumables 2) By End User: Hospitals, Specialized Diagnostic Centers, Specialized Research Institutes 3) By Instruments: Analyzers, Flow cytometers, Other Instruments 4) By Consumables: Reagents, Stains, Other Consumables 5) By Application: Drug Testing, Auto Immune Disease, Cancer, Diabetes Mellitus, Infectious Disease, Other Applications

Bioinformatics, which is connected to genetics and genomics, uses computer technology to gather, store, analyze, and share biological information and data such as DNA and amino acid sequences or annotations about those sequences.  The main product and service types of bioinformatics are knowledge management tools, data analysis platforms, and services. Knowledge management tools are technologies used by organizations to share information both internally and externally. The various applications include metabolomics, molecular phylogenetics, transcriptomics, proteomics, chemoinformatics, genomics, and others that are used by pharmaceutics, animal studies, agriculture, forensic science, and other end users. The bioinformatics market research report is one of a series of new reports from The Business Research Company that provides bioinformatics market statistics, including bioinformatics industry global market size, regional shares, competitors with a bioinformatics market share, detailed bioinformatics market segments, market trends and opportunities, and any further data you may need to thrive in the bioinformatics industry. This bioinformatics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global bioinformatics market will grow from $13.02 billion in 2022 to $14.68 billion in 2023 at a compound annual growth rate (CAGR) of 12.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global bioinformatics market is expected to grow to $24.46 billion in 2027 at a CAGR of 13.6%. Increasing demand for protein sequencing is driving growth in the bioinformatics market. Protein sequencing refers to the process of determining the sequence of amino acids in all or part of the proteins present in DNA, based on which specific functions, activities, origin, or localization of the protein are determined. Protein sequencing helps analysts to understand the distribution of amino acids along the sequences and the structure of proteins. With bioinformatics methods and databases, the capacity, structure, and developmental history of proteins can be effectively identified. The demand for protein sequencing is expected to grow on account of factors such as advancements in clinical mass spectrometry and analytical techniques, and the significant adoption of target-based drug development by pharmaceutical and biotechnology companies. For instance, in 2021, the total number of protein sequences in UniProtKB, which is a freely accessible database of protein sequence and functional information, increased to approximately 190 million. The lack of interoperability among various available data formats is acting as a restraint on the bioinformatics market. Various data formats come with differences in structures of data. There are numerous protein databases available through various resources, and each database chooses to represent proteins in a different format. Also, different data models such as object data model or relational data model are used while collecting data. Therefore, the problem of interoperability arises when a researcher tries to integrate the results of unique databases present in different data formats. Various data formats available for bioinformatics include Compressed Row Storage (CRS), Sparse Vector, Avro, Parquet and ORC (Optimized Row Compressed). According to a report by Pharmaphorum, an estimated 80% of the researchers’ time is spent on data grooming and only 20% on actual data analysis. This is essentially due to the lack of standardized file types and inconsistent data formatting, which means that every new program results in a new data format. The interoperability issues arising from the use of multiple data formats are affecting the market growth. Companies in the bioinformatics market are increasingly investing in the research and development of nanopore sequencing technology. Nanopore sequencing is a single molecule DNA sequencing technology that eliminates the need for Polymerase Chain Reaction or chemical labeling of the sample. This technology passes ionic current through nanopores (a pore of nanometer size) and when the biological molecules pass through the nanopores or near to it them this technology measures the changes in current which can be used to identify the molecule. Nanopore sequencing technology offers high throughput, low cost, longer reads (Sequence of a section of a unique fragment) to the analyst and helps in the collection of data which is an essential part of bioinformatics. For instance, in 2020, Oxford Nanopore Technologies raised $109.5 million to support the ramp of commercial and manufacturing operations and to further develop its nanopore technology. The bioinformatics market is governed by various regulatory bodies for quality and compliance of bioinformatics platforms. For instance, in India, the Biotechnology Industry Research Assistance Council (BIRAC), set up by Department of Biotechnology (DBT), Government of India, regulates the bioinformatics market. BIRAC introduces Technology Readiness Levels (TRLs) as a measure of estimating the maturity of technology while in the evaluation phases until these technologies are complete to be offered commercially. The TRL scale provides 9 technology readiness levels with TRL1 being the stage when the technology is ideated, and TRL9 being the stage when the technology is ready for commercial use. The manufacturers have to get past TRL9 to have their products available commercially and ready to be marketed. These TRL's consist of various levels of compliance and processes that the manufacturers must adhere to. The bioinformatics platform is evaluated for quality, feasibility, data privacy, and protection as per international standards. In September 2020, APIS Assay Technologies Ltd., a UK-based Biotechnology company acquired BeoGenomics for an undisclosed amount. With the addition of Beogenomics’ proven expertise in bioinformatics APIS Assay Technologies Ltd can more effectively capture the exciting opportunities presented in the bioinformatics space. BeoGenomics, a USA-based bioinformatics company that focuses on NGS, SNP chip, and GeneChip genomic data processing and analysis. Major players in the bioinformatics market are Agilent Technologies, Illumina, QIAGEN, Affymetrix, Thermo Fisher Scientific, BGI, Dassault Systems, Eurofins scientific, Bruker Daltonics, Biomax Informatix, DNASTAR, Partek, Geneva Bioinformatics, Perkinelmer Inc., Accelrys, SA Nonlinear Dynamics, Quest Diagnostics, Sophia Genetics, Waters Corporation, Permin Elmer Inc., Applied Biologicals Materials., Life Technologies, PerkinElmer, Waters Corporation, Sophia Genetics, Celera, Tripos, LP, Helicos Biosciences Incorporation, and IBM Life Sciences. North America was the largest region in the bioinformatics market in 2022. Western Europe was the second largest region in the global bioinformatics market. The regions covered in the global bioinformatics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the bioinformatics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The bioinformatics market includes revenues earned by entities by providing solutions which combine computer programming, information engineering, mathematics, and statistics to analyze biological data for drug discovery and preclinical studies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global bioinformatics market is segmented - 1) By Products and Serivces: Knowledge Management Tools, Data Analysis Platforms, Services 2) By Application: Metabolomics, Molecular Phylogenetics, Transcriptomics, Proteomics, Chemoinformatics, Genomics, Other Applications 3) By End Users: Pharmaceutics, Animal Study, Agriculture, Forensic Science, Other End Users

Biologics Market Definition

The biologics market consists of sales of biologics and related services by entities (organizations, sole traders and partnerships) that produce biologics or biosimilars to treat and prevent various microbial diseases and cancers. The biologics market comprises companies manufacturing biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, gene therapy tissues, somatic cells, vaccines, and allergenics. Biologics products are subjected to various laws and regulations that deal with patenting, testing, safety, efficacy, and marketing. Biologics products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies.

Cancer tumor profiling refers to a laboratory test that examines a sample of tumor tissue for specific genes, gene mutations (changes), proteins, or other biomarkers. Tumor profiling can help with treatment planning as well as predicting if cancer will recur or spread to other parts of the body. The main types of cancer and tumor profiling are lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, ovarian cancer, stomach cancer, pancreatic cancer, thyroid cancer, and other cancer types. The different technologies include next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), microarrays, and others, and involve various types of processes such as genomics, proteomics, epigenetics, metabolomics, and others. It is used in several applications, including personalized medicine, diagnostics, biomarker discovery, prognostics, and research applications. The cancer tumor profiling market research report is one of a series of new reports from The Business Research Company that provides cancer tumor profiling market statistics, including cancer tumor profiling industry global market size, regional shares, competitors with a cancer tumor profiling market share, detailed cancer tumor profiling market segments, market trends and opportunities, and any further data you may need to thrive in the cancer tumor profiling industry. This cancer tumor profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cancer tumor profiling market size grew from $9.62 billion in 2022 to $11.12 billion in 2023 at a compound annual growth rate (CAGR) of 15.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cancer tumor profiling market size is expected to grow to $18.18 billion in 2027 at a CAGR of 13.1%. The increasing incidences of cancer across the globe are expected to propel the growth of the cancer and tumor profiling market going forward. Cancer is a disease in which some cells in the body get uncontrollably large and spread to other parts of the body. As the number of cancer cases rises, so does the demand for cancer tumor profiling, which enables doctors to determine the severity of the disease. For instance, according to the World Health Organization (WHO), there are a 19.3 million increase in cancer cases in 2020, with over 10 million fatalities worldwide. Among these new cases, lung and breast cancer accounted for 23.1% of all cancer cases. In addition, according to the International Agency for Research on Cancer (IARC), 1 in 5 individuals will develop cancer during their lifetime, and 1 in 11 women and 1 in 8 men will die from it. Therefore, the increasing incidences of cancer across the globe drive the growth of the cancer and tumor profiling market. The increasing research and development activities have emerged as the key trend gaining popularity in cancer and tumor profiling market. Major companies operating in cancer and tumor profiling sector are focused on research and development activities to meet consumer demand and reinforce their position. For instance, in February 2020, QIAGEN N.V, a German company that develops sample and assay technology for applied testing, pharmaceutical development, molecular diagnostics, and academic research announced the Conformitè Europëenne (CE)-marking and commercialization of therascreen PIK3CA RGQ PCR Kit in Europe as a tool to help identify breast cancer patients with PIK3CA mutations. The therascreen PIK3CA test is a diagnostic assay for the detection of an activating mutation in the phosphatidyl 3-kinase catalytic subunit alpha (PIK3CA) gene, and first to allow testing of both DNA from plasma specimens or FFPE tissue. In July 2021, Labcorp, a US-based clinical laboratory-acquired OmniSeq for an undisclosed amount. The acquisition enables Labcorp to expand its array of clinical trial options and diagnostic tests for cancer patients and doctors. OmniSeq is a US-based company involved in solid tumor profiling that controls new sequencing technologies and supports drug development through pharmaceutical services. Major players in the cancer tumor profiling market are F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., QIAGEN, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString, NeoGenomics Laboratories, Lucence Health Inc., ACT Genomics Co. Ltd., Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation (Genomic Health Inc.), Guardant Health, and Foundation Medicine Inc. North America was the largest region in cancer and tumor profiling market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer and tumor profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cancer tumor profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The cancer tumor profiling market includes revenues earned by entities by sanger sequencing, pyro sequencing (PyroSeq), chromogenic/ fluorescence in situ hybridization (CISH/FISH) and fragment analysis (FA/Frag. Analysis). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cancer tumor profiling market is segmented - 1) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, Other Cancer Types 2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Other Technologies 3) By Process Type: Genomics, Proteomics, Epigenetics, Metabolomics, Other Types 4) By Application: Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications

In-vitro diagnostics devices and equipment is a gadget that tests human samples collected from the human body such as tissues and blood, with the goal of using the results to help with clinical diagnosis or management. The main types of in-vitro diagnostics equipment are point-of-care diagnostics devices and equipment, immunochemistry diagnostic devices and equipment, clinical chemistry diagnostics devices and equipment, molecular diagnostics devices and equipment, microbiology diagnostic devices and equipment, hemostasis diagnostic devices and equipment, hematology diagnostic devices, and equipment, and immunohematology diagnostic devices, and equipment. Hematology instruments are machines that analyze blood. The hematology instruments perform blood counts, detect proteins or enzymes, and help to diagnose illnesses or genetic defects. The type of expenditure is public and private. The products used are instruments/equipment and disposables. The end-users are hospitals and clinics, diagnostic laboratories, and others. The in-vitro diagnostics devices and equipment market research report is one of a series of new reports from The Business Research Company that provides in-vitro diagnostics devices and equipment market statistics, including in-vitro diagnostics devices and equipment industry global market size, regional shares, competitors with a in-vitro diagnostics devices and equipment market share, detailed in-vitro diagnostics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the in-vitro diagnostics devices and equipment industry. This in-vitro diagnostics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global in-vitro diagnostics market grew from $95.6 billion in 2022 to $106.53 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The in-vitro diagnostics market is expected to grow to $148.58 billion in 2027 at a CAGR of 8.7%. Demand for point-of-care diagnostic devices is increasing as they provide rapid results, are cost-effective, and have advanced diagnosis features for patients. The number of patients seeking treatments at local physician offices, retail clinics, and in-patient homes is increasing thus boosting the demand for point-of-care testing devices. Companies in this market are focusing on developing more user-friendly, reliable, and efficient point of care devices. For instance, in March 2020, Abbott launched Novel COVID-19 Test. The test will be used on the m2000 RealTime system available in hospitals and molecular labs in the U.S. Philips also launched a new handheld blood test, Handheld Minicare I-20 system used for diagnosing heart attacks in emergency departments which provide results within 10 minutes. IVD devices are being integrated with IoT and data analytics technologies to improve device efficiency and increase device security. IoT refers to a system of interconnected devices via communication technologies such as WIFI and Bluetooth for data transfer and accessing devices remotely. Data analytics refers to qualitative and quantitative techniques, used to infer actionable information from large data sets. These technologies are helping in enhancing IVD device functionality, mainly through remote monitoring, predictive maintenance for decreased downtime, and advanced data processing capabilities. Major companies in the in-vitro diagnostics devices and equipment market include Siemens Healthineers, F. Hoffmann-La Roche Ltd., Danaher (Beckman Coulter Inc), Abbott Laboratories Inc., and Thermo Fisher Scientific Inc. North America was the largest region in the global in-vitro diagnostics market in 2022. Asia-Pacific was the second largest region in the global in-vitro diagnostics market. The regions covered in the in-vitro diagnostics devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the in-vitro diagnostics devices and equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The in-vitro diagnostics devices and equipment market consist of sales of kits, reagents, piece of software, system, and instrument. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global in-vitro diagnostics market is segmented - 1) By Type: Point-of-Care Diagnostics Devices And Equipment, Immunochemistry Diagnostic Devices And Equipment, Clinical Chemistry Diagnostics Devices And Equipment, Molecular Diagnostics Devices And Equipment, Microbiology Diagnostic Devices And Equipment, Hemostasis Diagnostic Devices And Equipment, Hematology Diagnostic Devices And Equipment, Immunohematology Diagnostic Devices And Equipment 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables

The scientific research and development services are responsible for conducting original research on a systematic basis to gain new knowledge and to apply research findings or other scientific knowledge to create new or improved products or processes. The main types of scientific research and development services are social sciences and humanities services; physical, engineering, and life sciences; nanotechnology services; and biotechnology services. Nanotechnology is the near-atomic manipulation of matter to create new structures, materials, and technologies. Many fields, including medical, consumer goods, energy, materials, and manufacturing, will benefit from the technology. The different sizes of enterprises include large enterprises, small and medium enterprises, and involve various modes such as online and offline. The scientific research and development services market research report is one of a series of new reports from The Business Research Company that provides scientific research and development services market statistics, including scientific research and development services industry global market size, regional shares, competitors with a scientific research and development services market share, detailed scientific research and development services market segments, market trends and opportunities, and any further data you may need to thrive in the scientific research and development services industry. This scientific research and development services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global scientific research and development services market grew from $817.06 billion in 2022 to $897.68 billion in 2023 at a compound annual growth rate (CAGR) of 9.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, and affecting many markets across the globe. The scientific research and development service market is expected to grow from $1,254.27 billion in 2027 at a CAGR of 8.7%. The scientific research and development services market is expected to grow rapidly due to increasing lifestyle and chronic diseases. This is mainly due to unhealthy lifestyles, a growing ageing population, rising inactivity and obesity. According to the World Health Organization, chronic disease prevalence reached 57% globally in 2020. China and India together had about 193.4 million diabetic patients in 2019, and India is expected to have about 101 million diabetic patients by 2030. In the field of mental health, the World Health Organization predicts that one in every four people will be affected by a type of mental disorder such as depression, schizophrenia, or anxiety in the future. In response to this, national governments across the globe are rapidly increasing their medical research expenditure. For instance, China's medical research spending has increased and will reach $1 trillion in 2020. Therefore, increasing investment in medical research to treat chronic diseases is further driving the demand for scientific research and development services. The outbreak of COVID-19 disease (COVID-19) has acted as a restraint on the scientific research and development services market in 2020 as governments globally imposed lockdowns and restricted trade, thereby limiting the need for professional services. COVID-19 is an infectious disease with flu-like symptoms including fever, cough, and difficulty breathing. The virus was first identified in 2019 in Wuhan, Hubei province of the People’s Republic of China and has spread globally, including Western Europe, North America, and Asia. Steps by national governments to contain the transmission have resulted in a decline in economic activity with countries entering a state of "lock down." The outbreak has had a negative impact on businesses throughout 2020 and into 2021. However, it is expected that the scientific research and development services market will recover from the shock over the forecast period as it is a "black swan" event and not related to ongoing or fundamental weaknesses in the market or the global economy. 4D printing has evolved from 3D printing with the additional feature of changing the geometrical shape and mechanical properties, with time being integrated as an additional fourth dimension. One of the major drawbacks of 3D printing is that it can only take the shape in which it was originally made and is static and inanimate. With the latest development of 4D printing, objects can now be made with responsive materials with certain inherent properties that can change or transform in response to external stimuli. It has widespread applications in medical science, such as tissue regeneration in the biomedical field. For example, printed micro tissue from bio ink can undergo maturation via cellular coating to form functional tissue constructs such as engineered tissue constructs. Major biotechnology research companies using 4D bio printing technology include Poietis, Biolife4D, and Precise Bio. Major companies in the scientific research and development services market include IQVIA Holdings Inc., Battelle Memorial Institute, Defense Advanced Research Projects Agency, Lawrence Livermore National Laboratory LLC, Charles River Laboratories, Inc., Frog Design, Lawrence Berkeley National Lab, Jackson Laboratory, Piramal Group, and WuXi AppTec Co., Ltd. North America was the largest region in the scientific research and development services market in 2022. Asia-Pacific was the second largest region in the scientific research and development services market. The regions covered in the scientific research and development services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the scientific research and development services market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The scientific research and development services market consists of revenue earned by entities that engage in research and experimental development on a contract, consultancy, or outsourced basis. Scientific research and development services establishments undertake processes where human capital is the major input. They make available the knowledge and skills of their employees, often on an assignment basis, where an individual or team is responsible for the delivery of services to the client. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global scientific research and development services market is segmented - 1) By Type: Social Sciences And Humanities Services, Physical, Engineering, And Life Sciences, Nanotechnology Services, Biotechnology Services 2) By End User Size: Large Enterprise, Small and Medium Enterprise 3) By Mode: Online, Offline